Inhibition of the KAT2A-SRSF11 axis can promote RAD52 exon 10 skipping, thereby suppressing the interaction of RAD52 with RAD51, impairing HR and promoting radiation-induced tumor cell death across preclinical models (Fig. 6l), positioning this pathway as a therapeutic vulnerability. Here, RAD52 is linked to neoplasm.